Following a submission for alpelisib (Piqray®), as a treatment for postmenopausal women, and men, with advanced breast cancer, the SMC | Scottish Medicines Consortium (SMC) published not recommended alpelisib (Piqray) advice in December 2022. The marketing authorisation holder did not present a sufficiently robust clinical or economic analysis to gain a...